Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.64 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.64 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11227138 | 0.87 | ADORA2B (0.60) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL22398942 | 0.85 | ADORA2B (0.62) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL1065297 | 0.84 | ADORA2B (0.57) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL17626243 | 0.81 | SMN1; SMN2 (0.56) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL3776312 | 0.80 | ADORA2B (0.55) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL19969106 | 0.78 | ADORA2B (0.50) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL8569482 | 0.78 | ADORA2B (1.00) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL11698769 | 0.78 | ADORA2B (0.72) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL901194 | 0.78 | ADORA2B (1.00) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL5671 | 0.78 | ADORA2B (1.00) | ADORA2BPOLBPIK3CDADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | ADORA2B 314/4885POLB 4799/4885PIK3CD 2621/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | ADORA2B 55/4885POLB 4798/4885PIK3CD 3772/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ADORA2B 129/4885POLB 4804/4885PIK3CD 3752/4885 |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, P2RX3 | ADORA2B 55/4885POLB 4798/4885PIK3CD 3772/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | ADORA2B 129/4885POLB 4804/4885PIK3CD 3752/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ADORA2B 129/4885POLB 4804/4885PIK3CD 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.